Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. [electronic resource]
Producer: 19950929Description: 459-64 p. digitalISSN:- 1060-0280
- Anti-Bacterial Agents -- administration & dosage
- Cystic Fibrosis -- drug therapy
- Deoxyribonuclease I -- therapeutic use
- Double-Blind Method
- Expectorants -- therapeutic use
- Health Services -- economics
- Hospitalization -- economics
- Humans
- Prospective Studies
- Recombinant Proteins -- therapeutic use
- Respiratory Tract Infections -- drug therapy
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.